HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sensitization potential and reactogenicity of varying doses of BCG plus killed Mycobacterium leprae: an extended study.

Abstract
This study is an extension of a previous study on an antileprosy combination vaccine of BCG plus killed Mycobacterium leprae (KML) regarding its sensitization potential and reactogenicity. The study was extended to see if by reducing the dose of BCG in the combination vaccine the incidence of suppurative adenitis could be reduced without a significant reduction in the level of postvaccination skin-test responses. The study included 860 individuals, and three preparations of the combination vaccine [BCG 0.05 mg + 6 x 10(8) KML (I), BCG 0.05 mg + 5 x 10(7) KML (II), BCG 0.01 mg + 5 x 10(7) KML (III)] along with normal saline (i.v.) were used. Each individual received one of these four preparations by random allocation. They were also tested with Rees' M. leprae soluble antigen (MLSA) and lepromin A 12 weeks after vaccination. Reactions to the MLSA were measured after 48 hr; reactions to lepromin A after 48 hr and 3 weeks. The character and size of the local response at the vaccination site were recorded at the third, eighth, and 15th week postvaccination. The results of the study showed that by halving the dose of BCG in the combination vaccine BCG plus 6 x 10(8) KML a) the incidence of suppurative regional adenitis was reduced significantly, b) there was no significant change in the post-vaccination response at 12 weeks as measured by Rees' MLSA and lepromin A, and c) the evolution of the vaccination lesion was somewhat prolonged. This dose was found satisfactory for use in a comparative antileprosy vaccine trial in South India.
AuthorsM D Gupte, R S Vallishayee, L J De Britto, D S Anantharaman
JournalInternational journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association (Int J Lepr Other Mycobact Dis) Vol. 61 Issue 4 Pg. 563-70 (Dec 1993) ISSN: 0148-916X [Print] United States
PMID8151187 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • BCG Vaccine
  • Bacterial Vaccines
  • Vaccines, Inactivated
  • anti-leprosy vaccine
  • Lepromin
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • BCG Vaccine (adverse effects)
  • Bacterial Vaccines (adverse effects)
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Immunologic
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Lepromin (immunology)
  • Leprosy (prevention & control)
  • Lymphadenitis (etiology)
  • Male
  • Middle Aged
  • Mycobacterium leprae (immunology)
  • Vaccination (adverse effects)
  • Vaccines, Inactivated (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: